PremiumCompany AnnouncementsDenali Therapeutics Enters Registration Rights Agreement Denali Therapeutics price target lowered to $27 from $28 at BofA Denali Therapeutics price target lowered to $30 from $35 at B. Riley PremiumThe FlyDenali Therapeutics price target lowered to $32 from $80 at H.C. Wainwright Denali Therapeutics: Strategic Advancements and Promising Pipeline Drive Buy Rating Denali Therapeutics reports Q1 EPS (78c), consensus (70c) PremiumThe FlyDenali Therapeutics price target lowered to $28 from $30 at BofA Denali Therapeutics assumed with an Overweight at Morgan Stanley Denali Therapeutics: Promising Growth Prospects Despite Recent Setbacks 
